Sponsored by
This study analyzed data from a French national network database to compare two different chemotherapy regimens (procarbazine-CCNU-vincristine [PCV] versus temozolomide [TMZ]) in patients with newly diagnosed IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma. The results showed patients who received first-line PCV with radiation therapy lived longer than those who received TMZ with radiation therapy. After 5 years, 89% of patients treated with PCV were still alive, compared to 75% of those treated with TMZ. At 10 years, the survival rate was 72% for PCV and 60% for TMZ. While TMZ is generally easier for patients to tolerate, these results suggest it may not be as effective as PCV in this particular cohort.